Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subgroup characterized by a high risk of resistance to chemotherapies and high relapse potential. TNBC shows inter-and intra-tumoral heterogeneity; more than half expresses high EGFR levels and about 30% are classifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Dakroub, Rayan, Huard, Solène, Hajj-Younes, Yara, Suresh, Samyuktha, Badran, Bassam, Fayyad-Kazan, Hussein, Dubois, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637385/
https://www.ncbi.nlm.nih.gov/pubmed/37954171
http://dx.doi.org/10.2147/BCTT.S430513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637385/
https://www.ncbi.nlm.nih.gov/pubmed/37954171
http://dx.doi.org/10.2147/BCTT.S430513

Ejemplares similares